OROS Methylphenidate Long-Term Study in ADHD
Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
2003-05-01
|
| Series: | Pediatric Neurology Briefs |
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/1517 |